CLSPN is a potential biomarker associated with poor prognosis in low-grade gliomas based on a multi-database analysis
Yulong Jia,Xingbo Cheng,Wenjia Liang,Shaochong Lin,Pengxu Li,Zhaoyue Yan,Meng Zhang,Wen Ma,Chenchen Hu,Baoya Wang,Zhendong Liu
DOI: https://doi.org/10.1016/j.retram.2022.103345
IF: 4.192
2022-09-01
Current Research in Translational Medicine
Abstract:BackgroundThe oncogene CLSPN, also known as claspin, has regulatory effects in a variety of tumours; however, it is not clear whether CLSPN is a therapeutic target in low-grade gliomas (LGG). In this study, the prognostic value of CLSPN in LGG and its role as an immunotherapeutic target were evaluated.MethodsTranscriptome and methylation data for thousands of patients with glioma were collected from various databases, including The Cancer Genome Atlas, Chinese Glioma Genome Atlas, and Gene Expression Omnibus. Subsequently, a series of bioinformatics methods were used to evaluate the relationships between CLSPN and prognosis, clinical features, methylation status, immune cells, and molecular signaling pathways in LGG.ResultsCLSPN expression levels were positively correlated with major malignant characteristics of LGG, and low expression of CLSPN was associated with a better prognosis. The methylation sites cg04263115 and cg06100291 negatively regulated the expression of CLSPN, and increased methylation levels at these sites were related to a longer survival time in patients with LGG. CLSPN was positively correlated with tumour-infiltrating immune cells and showed high copy number variation in these cells. There was a positive regulatory relationship between CLSPN expression and programmed death-1 (PD-1) and programmed cell death ligand 1 (PD-L1). A gene set enrichment analysis revealed that CLSPN activates a variety of cancer signaling pathways.ConclusionCLSPN was identified as an independent risk factor for LGG with excellent prognostic value.
medicine, research & experimental